Good
Mostly Aligned
Patient Risk:
Low
Summary
Four of five statements are directly supported by the provided label excerpts (Description and Dosage Forms/Strengths). The remaining statement about generic products/therapeutic equivalence is not supported by the provided label text and is therefore treated as partially unsupported.
Category Scores
Accurate Statements
Crestor’s generic name is rosuvastatin.
11 DESCRIPTION: “CRESTOR (rosuvastatin) …”
Crestor (rosuvastatin) is available in strengths including rosuvastatin calcium 5 mg, 10 mg, 20 mg, or 40 mg.
11 DESCRIPTION: “CRESTOR tablets for oral use contain rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg … (equivalent to 5.2 mg, 10.4 mg, 20.8 mg, and 41.6 mg rosuvastatin calcium).”; 3 DOSAGE FORMS AND STRENGTHS: “5 mg … 10 mg … 20 mg … 40 mg”
Inactive ingredients and pill appearance can differ among generic rosuvastatin products.
11 DESCRIPTION lists inactive ingredients for CRESTOR tablets, and 3 DOSAGE FORMS AND STRENGTHS describes tablet appearance by strength; however, the provided label excerpts do not explicitly discuss generics. This statement is treated as partially label-grounded via CRESTOR-specific inactive ingredients/appearance differences across strengths, but not across generic manufacturers.
Any generic Crestor product should contain the same active ingredient: rosuvastatin.
11 DESCRIPTION: “CRESTOR (rosuvastatin) …”; CRESTOR tablets contain rosuvastatin in multiple strengths (active ingredient). The label excerpt provided does not explicitly address generics, but it supports that CRESTOR’s active ingredient is rosuvastatin.
Unsupported Statements
Inactive ingredients and pill appearance can differ among generic rosuvastatin products.
The provided label excerpts describe CRESTOR inactive ingredients and tablet appearance by CRESTOR strength, but do not state that generic rosuvastatin products differ from CRESTOR (or from each other) in inactive ingredients or appearance.
Clinicians typically treat generic rosuvastatin as therapeutically equivalent to brand Crestor because they share the same active ingredient.
The provided prescribing information excerpts do not discuss clinician practice, therapeutic equivalence, or inter-product interchangeability for generics vs brand.
Contradictions
Important Omissions
No omission evaluation is scored because the AI claims were limited to active ingredient/strength/consistency and do not request dosing, contraindications, boxed warnings, interactions, monitoring, or specific populations.
Importance:
Safety Assessment
Potential Patient Risk:
Low
The claims are general product identification statements. The only potentially problematic part is the unsupported assertion about therapeutic equivalence/interchangeability, which is not established in the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Generic-product interchangeability/therapeutic equivalence and generic appearance differences are not supported by the provided CRESTOR label excerpts.
Suggested Improvement
Limit claims to label-supported facts about CRESTOR’s active ingredient (rosuvastatin) and strengths/CRESTOR formulation/appearance, and avoid statements about generic equivalence or typical clinician treatment unless explicitly present in the label text provided.